Meeting
2023 ASCO Annual Meeting
Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.
Authors
Juan José Serrano Domingo
Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
Juan José Serrano Domingo , David Cordero , Miriam Menacho , Jose Manuel del Rey , Jesús Chamorro , Diana I. Rosero , Pilar Sotoca , Laura del Campo , Gonzalo Alonso , Cristina Saavedra Serrano , María Fernández-Abad , Maria Gion Cortes , Eva M. Guerra , Noelia Martinez-Jañez , Elena Lopez-Miranda , Elena Maria Vida Navas , Raquel Fuentes Mateos , CARMEN GUILLEN PONCE , Maria Teresa Salazar , Alfonso Cortés Salgado
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 567)
DOI
10.1200/JCO.2023.41.16_suppl.567
Abstract #
567
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
An exploratory study to determine if BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity.
First Author: Roohi Ismail-Khan
Poster
2022 ASCO Annual Meeting
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.
First Author: Dmitry Yu. Gvaldin
Poster
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
First Author: Jenny Furlanetto
Poster
2016 ASCO Annual Meeting
Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.
First Author: Susan Faye Dent